[
  {
    "text": "1.83 \"Program Inventions\"' means any Know-How conceived, reduced to practice, developed, made or otherwise generated by or on behalf of a",
    "bbox": [
      156,
      83,
      1000,
      95
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Party or its Affiliates or Sublicensees in connection with the Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "under this Agreement or any Ancillary Agreement, including all rights, title and interest in and to the intellectual property rights therein.",
    "bbox": [
      111,
      115,
      1000,
      127
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.84 \"Publication\"' means any release of information, including any presentation, which information (a) has not been disclosed pursuant to Section",
    "bbox": [
      155,
      145,
      1000,
      158
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "11.3 or (b) has not previously been publicly disclosed.",
    "bbox": [
      112,
      161,
      505,
      173
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.85 \"Registrational Clinical Trial' means a Clinical Trial of a Product designed to be adequate to achieve Regulatory Approval of such Product",
    "bbox": [
      155,
      191,
      1000,
      204
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and that would satisfy the requirements of 21 C.F.R 312.21(c), as amended, or corresponding foreign regulations, regardless of whether such trial is",
    "bbox": [
      111,
      207,
      1000,
      220
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "referred to as a \"phase 2b clinical trial\", \"phase 2b/3 clinical trial'' or \"phase 3 clinical trial', but excluding, for clarity, any investigator-initiated Clinical",
    "bbox": [
      111,
      223,
      1000,
      235
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Trials.",
    "bbox": [
      110,
      237,
      156,
      251
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.86 \"Regulatory Approval' means, with respect to a country or jurisdiction, any and all approvals (including Marketing Approvals), licenses,",
    "bbox": [
      157,
      270,
      1000,
      282
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Product in such country or jurisdiction,",
    "bbox": [
      111,
      285,
      1000,
      297
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "including, where applicable, (a) pricing or reimbursement approval in such country or jurisdiction, (b) pre- and post-approval marketing authorizations",
    "bbox": [
      111,
      301,
      1000,
      313
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "(including any prerequisite Manufacturing approval or authorization related thereto) and (c) labeling approval.",
    "bbox": [
      112,
      316,
      914,
      329
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.87 \"Regulatory Authority\" means any applicable Governmental Authority involved in the granting Regulatory Approvals for the Products or",
    "bbox": [
      157,
      347,
      1000,
      359
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "otherwise exercising authority with respect to biopharmaceutical products in the applicable country or jurisdiction, including the FDA, the EMA, the",
    "bbox": [
      111,
      363,
      1000,
      375
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "PMDA and any corresponding national or regional regulatory authorities.",
    "bbox": [
      110,
      378,
      646,
      390
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.88 \"Regulatory Exclusivity\" means any rights or protections which are recognized, afforded or granted by the FDA or any other Regulatory",
    "bbox": [
      156,
      408,
      1000,
      422
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Authority in any country or region of the Territory pursuant to Applicable Laws of such country or region, in association with the marketing",
    "bbox": [
      111,
      424,
      1000,
      438
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "authorization of the Product, providing the Product[***] a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or",
    "bbox": [
      111,
      440,
      1000,
      452
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission,",
    "bbox": [
      112,
      456,
      1000,
      468
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.89 \"Regulatory Materials' all (a) applications (including all INDs), registrations, licenses, authorizations and approvals (including MAAs and",
    "bbox": [
      156,
      502,
      1000,
      514
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event",
    "bbox": [
      110,
      533,
      1000,
      546
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "files and complaint files, (c) clinical and other data contained, referenced or otherwise relied upon in any of the foregoing, and (d) for clarity, any drug",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "master file.",
    "bbox": [
      110,
      565,
      188,
      575
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.90 \"Required Phase 4 Studies\"' means any Phase 4 Studies that are required by the applicable Regulatory Authority to be conducted as a.",
    "bbox": [
      157,
      595,
      1000,
      607
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "condition for Regulatory Approval, including Regulatory Approval for a label expansion, whether or not also required for pricing or reimbursement.",
    "bbox": [
      111,
      610,
      1000,
      623
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "approval.",
    "bbox": [
      110,
      625,
      181,
      639
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "13",
    "bbox": [
      660,
      640,
      681,
      654
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.83 \"Program Inventions\"' means any Know-How conceived, reduced to practice, developed, made or otherwise generated by or on behalf of a",
    "bbox": [
      156,
      83,
      1000,
      95
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "Party or its Affiliates or Sublicensees in connection with the Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "under this Agreement or any Ancillary Agreement, including all rights, title and interest in and to the intellectual property rights therein.",
    "bbox": [
      111,
      115,
      1000,
      127
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.84 \"Publication\"' means any release of information, including any presentation, which information (a) has not been disclosed pursuant to Section",
    "bbox": [
      155,
      145,
      1000,
      158
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "11.3 or (b) has not previously been publicly disclosed.",
    "bbox": [
      112,
      161,
      505,
      173
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.85 \"Registrational Clinical Trial' means a Clinical Trial of a Product designed to be adequate to achieve Regulatory Approval of such Product",
    "bbox": [
      155,
      191,
      1000,
      204
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "and that would satisfy the requirements of 21 C.F.R 312.21(c), as amended, or corresponding foreign regulations, regardless of whether such trial is",
    "bbox": [
      111,
      207,
      1000,
      220
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "referred to as a \"phase 2b clinical trial\", \"phase 2b/3 clinical trial'' or \"phase 3 clinical trial', but excluding, for clarity, any investigator-initiated Clinical",
    "bbox": [
      111,
      223,
      1000,
      235
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "Trials.",
    "bbox": [
      110,
      237,
      156,
      251
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.86 \"Regulatory Approval' means, with respect to a country or jurisdiction, any and all approvals (including Marketing Approvals), licenses,",
    "bbox": [
      157,
      270,
      1000,
      282
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Product in such country or jurisdiction,",
    "bbox": [
      111,
      285,
      1000,
      297
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "including, where applicable, (a) pricing or reimbursement approval in such country or jurisdiction, (b) pre- and post-approval marketing authorizations",
    "bbox": [
      111,
      301,
      1000,
      313
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "(including any prerequisite Manufacturing approval or authorization related thereto) and (c) labeling approval.",
    "bbox": [
      112,
      316,
      914,
      329
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.87 \"Regulatory Authority\" means any applicable Governmental Authority involved in the granting Regulatory Approvals for the Products or",
    "bbox": [
      157,
      347,
      1000,
      359
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "otherwise exercising authority with respect to biopharmaceutical products in the applicable country or jurisdiction, including the FDA, the EMA, the",
    "bbox": [
      111,
      363,
      1000,
      375
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "PMDA and any corresponding national or regional regulatory authorities.",
    "bbox": [
      110,
      378,
      646,
      390
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.88 \"Regulatory Exclusivity\" means any rights or protections which are recognized, afforded or granted by the FDA or any other Regulatory",
    "bbox": [
      156,
      408,
      1000,
      422
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "Authority in any country or region of the Territory pursuant to Applicable Laws of such country or region, in association with the marketing",
    "bbox": [
      111,
      424,
      1000,
      438
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "authorization of the Product, providing the Product[***] a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or",
    "bbox": [
      111,
      440,
      1000,
      452
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission,",
    "bbox": [
      112,
      456,
      1000,
      468
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.89 \"Regulatory Materials' all (a) applications (including all INDs), registrations, licenses, authorizations and approvals (including MAAs and",
    "bbox": [
      156,
      502,
      1000,
      514
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact",
    "bbox": [
      110,
      517,
      1000,
      530
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event",
    "bbox": [
      110,
      533,
      1000,
      546
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "files and complaint files, (c) clinical and other data contained, referenced or otherwise relied upon in any of the foregoing, and (d) for clarity, any drug",
    "bbox": [
      110,
      548,
      1000,
      561
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "master file.",
    "bbox": [
      110,
      565,
      188,
      575
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "1.90 \"Required Phase 4 Studies\"' means any Phase 4 Studies that are required by the applicable Regulatory Authority to be conducted as a.",
    "bbox": [
      157,
      595,
      1000,
      607
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "condition for Regulatory Approval, including Regulatory Approval for a label expansion, whether or not also required for pricing or reimbursement.",
    "bbox": [
      111,
      610,
      1000,
      623
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "approval.",
    "bbox": [
      110,
      625,
      181,
      639
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "13",
    "bbox": [
      660,
      640,
      681,
      654
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  },
  {
    "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
    "bbox": [
      133,
      1000,
      581,
      1000
    ],
    "label": 30,
    "category": "Irrevocable Or Perpetual License"
  }
]